Semaglutide is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Semaglutide is the active ingredient of these drugs:
Australia Austria Brazil Canada Cyprus
Brazil Canada Finland Ireland Lithuania
Canada Lithuania Poland United States
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):